Evercore ISI Begins Coverage on Repligen (NASDAQ:RGEN)

Evercore ISI initiated coverage on shares of Repligen (NASDAQ:RGEN) in a report published on Tuesday, MarketBeat reports. The firm issued an in-line rating and a $155.00 price objective on the biotechnology company’s stock.

Several other brokerages also recently commented on RGEN. JPMorgan Chase & Co. raised their target price on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. TD Cowen started coverage on shares of Repligen in a report on Monday, February 10th. They set a “buy” rating and a $200.00 target price on the stock. Canaccord Genuity Group raised their target price on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a report on Friday, February 21st. HC Wainwright reiterated a “buy” rating and issued a $180.00 price objective on shares of Repligen in a report on Friday, February 21st. Finally, StockNews.com downgraded shares of Repligen from a “hold” rating to a “sell” rating in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $178.64.

Repligen Stock Performance

Shares of NASDAQ:RGEN opened at $139.34 on Tuesday. The company has a market capitalization of $7.81 billion, a price-to-earnings ratio of -273.22, a P/E/G ratio of 4.54 and a beta of 0.95. The firm’s 50 day simple moving average is $156.47 and its 200 day simple moving average is $148.40. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $200.23.

Repligen (NASDAQ:RGEN) last announced its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. As a group, sell-side analysts forecast that Repligen will post 1.72 earnings per share for the current year.

Insider Activity at Repligen

In other news, Director Margaret Pax bought 250 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 1.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Repligen

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Signaturefd LLC boosted its position in Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 124 shares during the period. Sava Infond d.o.o. bought a new position in Repligen during the fourth quarter worth $29,000. Raiffeisen Bank International AG bought a new position in Repligen during the fourth quarter worth $29,000. Resources Management Corp CT ADV bought a new position in Repligen during the third quarter worth $37,000. Finally, Quarry LP boosted its position in Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 239 shares during the period. 97.64% of the stock is owned by institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.